To Name :
To Email :
From Name :
From Email :
Comments :

Clinical Reviews


Postpartum hemorrhage: 11 critical questions, answered by an expert

A playbook on postpartum hemorrhage, from prevention to essential management

January 2011 · Vol. 23, No. 1

IN THIS ARTICLE

We know the potentially tragic outcome of postpartum hemorrhage (PPH): Worldwide, more than 140,000 women die every year as a result of PPH—one death every 4 minutes! Lest you dismiss PPH as a concern largely for developing countries, where it accounts for 25% of maternal deaths, consider this: In our highly developed nation, it accounts for nearly 8% of maternal deaths—a troubling statistic, to say the least.

The significant maternal death rate associated with PPH, and questions about how to reduce it, prompted the editors of OBG Management to talk with Haywood L. Brown, MD. Dr. Brown is Roy T. Parker Professor and chair of obstetrics and gynecology at Duke University Medical Center in Durham, NC. He is also a nationally recognized specialist in maternal-fetal medicine. In this interview, he discusses the full spectrum of management of PPH, from proactive assessment of a woman’s risk to determination of the cause to the tactic of last resort, emergent hysterectomy.


Uterine atony is the leading cause of postpartum hemorrhage. When medical management fails to stanch the bleeding, bilateral uterine artery ligation is one surgical option.

1. What is PPH?

OBG Management: Dr. Brown, let’s start with a simple but important aspect of PPH—how do you define it?

Dr. Brown: Obstetric hemorrhage is excessive bleeding that occurs during the intrapartum or postpartum period—specifically, estimated blood loss of 500 mL or more after vaginal delivery or 1,000 mL or more after cesarean delivery.

PPH is characterized as early or late, depending on whether the bleeding occurs within 24 hours of delivery (early, or primary) or between 24 hours and 6 to 12 weeks postpartum (late, or secondary). Primary PPH occurs in 4% to 6% of pregnancies.

Another way to define PPH: a decline of 10% or more in the baseline hematocrit level.

OBG Management: How do you measure blood loss?

Dr. Brown: The estimation of blood loss after delivery is an inexact science and typically yields an underestimation. Most clinicians rely on visual inspection to estimate the amount of blood collected in the drapes after vaginal delivery and in the suction bottles after cesarean delivery. Some facilities weigh lap pads or drapes to get a more accurate assessment of blood loss. In a routine delivery, no specific calorimetric measuring devices are used to estimate blood loss.

At my institution, we make an attempt to estimate blood loss at every delivery—vaginal or cesarean—and record the estimate. By doing this routinely, the clinician improves in accuracy and becomes more adept at identifying excessive bleeding.

OBG Management: Is blood loss the only variable that arouses concern about possible hemorrhage?

Dr. Brown: Because pregnant women experience an increase in blood volume and physiologic cardiovascular changes, the usual sign of significant bleeding can sometimes be masked. Therefore, any changes in maternal vital signs, such as a drop in blood pressure, tachycardia, or sensorial changes, may suggest that more blood has been lost than has been estimated.

Hypotension, dizziness, tachycardia or palpitations, and decreasing urine output will typically occur when more than 10% of maternal blood volume has been lost. In this situation, the patient should be given additional fluids, and a second intravenous line should be started using large-bore, 14-gauge access. In addition, the patient’s hemoglobin and hematocrit levels should be measured. All these actions constitute a first-line strategy to prevent shock and potential irreversible renal failure and cardiovascular collapse.

3 levels of hemorrhage—and how to manage them

Low: 500 to 1,000 mL

This level of hemorrhage should be anticipated and can usually be managed with uterine massage and administration of a uterotonic agent, such as oxytocin. Intravenous fluids and careful monitoring of maternal vital signs are also warranted.

Active management of the third stage of labor has been shown to reduce the risk of significant postpartum hemorrhage (PPH). Active management includes:

  • administration of a uterotonic agent immediately after delivery of the infant
  • early cord clamping and cutting
  • gentle cord traction with uterine counter-traction when the uterus is well contracted
  • uterine massage.2

If these methods are unsuccessful in correcting the atony, uterotonics such as a prostaglandin (rectally administered misoprostol [800 mg] or intramuscular carboprost tromethamine [Hemabate; 250 μg/mL]) will usually succeed.

Medium: 1,000 to 1,500 mL

Blood loss of this volume is usually accompanied by cardiovascular signs, such as a fall in blood pressure, diaphoresis, and tachycardia. Women with this level of hemorrhage exhibit mild signs of shock.

It is important to correct maternal hypotension with fluids, restabilize vital signs, and resolve the bleeding expeditiously. If uterotonics and massage fail to stanch the bleeding, consider placing a balloon (e.g., Bakri balloon). Once the balloon is placed and inflated, it can be left for as long as 24 hours or until the uterus regains its tone.

Be sure to check hemoglobin and hematocrit levels and transfuse the patient, if necessary, especially if vital signs have not stabilized.

High: 1,500 to 2,000 mL, or greater

This is a medical emergency that must be managed aggressively to prevent morbidity and death. Blood loss of this volume will usually bring significant cardiovascular changes, such as hypotension, tachycardia, restlessness, pallor, oliguria, and cardiovascular collapse from hemorrhagic shock. this degree of blood loss means that the patient has lost 25% to 35% of her blood volume and will need blood-product replacement to prevent coagulation and the cascade of hemorrhage.

If conservative measures are unsuccessful, timely surgical intervention with B-Lynch suture, uterine vessel ligation, or hysterectomy is lifesaving.—HAYWOOD L. BROWN, MD

2. What causes PPH?

OBG Management: Why does PPH occur?

Dr. Brown: The leading cause is uterine atony, a failure of the uterus to contract and undergo resolution following delivery of an infant. Approximately 80% of cases of early PPH are related to uterine atony.

There are other causes of PPH:

  • lacerations of the genital tract (perineum, vagina, cervix, or uterus)
  • retained fragments of placental tissue
  • uterine rupture
  • blood clotting abnormalities
  • uterine inversion.

3. Is it possible to prepare for PPH?

OBG Management: What is the starting point for management of PPH?

Dr. Brown: Prevention of, and preparation for, hemorrhage begin well before delivery. During the prenatal period, for example, it is important to assess the woman’s level of risk for PPH. Among the variables that increase her risk:

  • any situation that leads to overstretching of the uterus, including multiple gestation, whether delivery is vaginal or cesarean
  • a history of PPH.

It is important that women with these characteristics maintain adequate hemoglobin and hematocrit levels by taking vitamin and iron supplements in the antepartum period.

In addition, women who have abnormal placental implantation, such as placenta previa, are at risk for bleeding during the antepartum period and during cesarean delivery. They should maintain a hematocrit in the mid-30s because of expected blood loss during delivery.

OBG Management: What preparatory steps should be taken at the time of hospital admission if a woman has an elevated risk of bleeding?

Dr. Brown: When the patient is hospitalized in anticipation of delivery—whether vaginal or cesarean—the team should assess her hemoglobin and hematocrit levels and type and screen for possible transfusion. The patient should also be apprised of her risk and the potential for transfusion.

Last, the anesthesia team should be alerted to her risk factors for postpartum bleeding.

4. What intrapartum variables signal an increased risk of PPH?

OBG Management: During labor and delivery, what variables signal an elevated risk of bleeding?

Dr. Brown: Risk factors for hemorrhage become more apparent during this period. They include prolonged or rapid labor, prolonged use of oxytocin, operative delivery, infections such as chorioamnionitis, and vaginal birth after cesarean delivery (VBAC).

Bleeding with VBAC merits special attention because it could signal uterine rupture. Women who have a low transverse uterine scar and who undergo VBAC have a risk of uterine scar separation during labor of 0.5% to 1%.

OBG Management: What about retained placenta or a placenta that requires manual removal?

Dr. Brown: These intrapartum variables are not as easy to anticipate. They may suggest a condition such as placenta accreta, especially if the patient is undergoing VBAC.

Uterine inversion can also lead to hemorrhage and is a medical emergency.

OBG Management: What steps should be taken at the time of labor to ensure a safe outcome?

Dr. Brown: A type and screen should be available for all women on labor and delivery, and the team should anticipate the need to cross-match for blood if there is a high potential for transfusion. For example, a woman known to have anemia (hematocrit <30%) should have a cross-match performed so that blood can be prepared for transfusion.

In addition, women who are undergoing planned delivery for placental implantation disorders should have blood in the operating room ready for transfusion when cesarean is performed. These women are at great risk of hemorrhage and peripartum hysterectomy.

5. What first-line strategies do you recommend?

OBG Management: Do you recommend oxytocin administration and fundal massage for every patient after delivery of the infant?

Dr. Brown: Yes. These strategies lessen the risk of uterine atony and excessive bleeding after vaginal delivery. At the time of cesarean delivery, expression of the placenta and uterine massage, along with oxytocin administration, reduce the risk of excessive blood loss.

If bleeding continues even after the uterus begins to contract, look for other causes of the bleeding, such as uterine laceration or retained placental fragments.

OBG Management: What uterotonic agents do you use besides oxytocin, and when?

Dr. Brown: Oxytocin is the first-line agent for control of hemorrhage. I give a dosage of 10 to 40 U/L of normal saline or lactated Ringer solution, infused continuously. Alternatively, 10 U can be given intramuscularly (IM). Second-line drugs and their dosages are listed in the TABLE.

Uterotonic agents and how to administer them

Drug

Dosage and route

Considerations

FIRST-LINE

Oxytocin

10–40 U/L of saline or lactated ringer solution, infused continuously, Or 10 U IM

The preferred drug—often the only one needed

SECOND-LINE

Misoprostol (Cytotec, Prostaglandin e1)

800–1,000 μg can be given rectally

Often, the second-line drug that is given just after oxytocin because it is easy to administer

Methylergonovine (Methergine)

0.2 mg IM every 2–4 hr

Contraindicated in hypertension

Carboprost tromethamine (Hemabate)

0.25 mg IM every 15–90 minutes (maximum of 8 doses)

Avoid in patients who have asthma. Contra-indicated in hepatic, renal, and cardiac disease

Dinoprostone (Prostin e2)

20 mg suppository can be given vaginally or rectally every 2 hours

Avoid in hypotension

6. How do you assess the patient once PPH is identified?

OBG Management: How do you assess the patient after hemorrhage begins?

Dr. Brown: We recheck the hemoglobin and hematocrit levels and monitor vital signs for hypotension and tachycardia. We also begin fluid resuscitation and type and cross-match blood and blood products.

A delayed response to hemorrhage raises the risk of maternal morbidity and death.

We notify the anesthesia team when it seems likely that a surgical approach to the hemorrhage will be needed. And we notify interventional radiology if the bleeding may respond to uterine artery embolization.

7. Why is it important to replace blood products?

OBG Management: You’ve been known to say, “The more blood a patient loses, the more blood she loses.” What do you mean by that?

Dr. Brown: Excessive bleeding leads to a loss of critical clotting factors that are made in the liver. Once the clotting factors are depleted, the woman is at risk of coagulopathy or disseminated intravascular coagulation. This depletion potentiates the cycle of hemorrhage. When that occurs, the hemorrhage can be controlled only with transfusion of red blood cells (RBCs) and replacement of clotting factors with fresh frozen plasma, platelets, and cryoprecipitate, along with prompt correction of the process that is causing the bleeding.

OBG Management: What blood products do you administer to a patient with hemorrhage, and when?

Dr. Brown: The first line of defense for blood loss requiring transfusion is packed RBCs. Each unit of packed cells increases the hematocrit by 3% and hemoglobin by 1 g/dL, assuming bleeding is under control. After that, consider:

  • Platelets. Depending on the severity of the hemorrhage and the level of platelets once the coagulation status is checked, platelets can be given. A 50-mL unit can raise the platelet count 5,000–10,000/mm3. Platelets should be considered if the count is below 50,000/mm3.
  • Fresh frozen plasma should be given to replace clotting factors. Fresh frozen plasma contains fibrinogen, antithrombin III, factor V, and factor VIII. Each unit of fresh frozen plasma increases the fibrinogen level by 10 mg/dL.
  • Cryoprecipitate contains fibrinogen, factors VIII and XIII, and von Willebrand factor. Each unit of cryoprecipitate increases fibrinogen by 10 mg/dL.
  • Factor VII can be given if the hemorrhage is still active, but it should only be given after fresh frozen plasma and cryo-precipitate have been given to replace clotting factors. Factor VII is ineffective without clotting factor replacement prior to its administration. This medication is associated with a high risk of thromboembolism. It is also expensive.
  • Synthetic fibrinogen (RiaSTAP) is available for use in the United States, but it has FDA approval only for the treatment of acute bleeding in patients who have congenital fibrinogen deficiency. It may have potential for use during PPH when essential clotting factors have been depleted.
Continued...
Did you miss this content?
Avoiding “shotgun” treatment: New thoughts on endometriosis-associated pelvic pain